[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Korea United Pharm. Inc.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":103},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,41,63,84],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100648894","phase-1-safety-pk-and-pd-comparison-of-ui059-and-uic202201-in-healthy-volunteers-100648894",false,"NCT07727629","Safety, PK, and PD Comparison of UI059 and UIC202201 in Healthy Volunteers","A Randomized, Open-label, Multiple-dose, Crossover Phase 1 Clinical Trial to Compare and Evaluate the Safety, Pharmacokinetics and Pharmacodynamics Characteristics After Oral Administration of UI059 and UIC202201 in Healthy Adult Volunteers","Inclusion Criteria:\n\n* Healthy adult volunteers aged 19 years or older at the time of screening.\n* Weight and Body Mass Index (BMI) at screening as follows:\n\n  * Body weight: ≥50.0kg for males, ≥45.0kg for females.\n  * BMI: ≥18.0mg\u002Fm2 and ≤ 30.0kg\u002Fm2\n* Subjects who do not have congenital or chronic diseases requiring treatment and have no pathological symptoms or findings based on medical examination.\n* Subjects judged suitable for the clinical trial based on laboratory tests, vital signs, physical examination, and 12-lead ECG conducted at screening.\n* Subjects who test negative for H.pylori antibody at screening.\n* Subjects who voluntarily decide to participate and provide written informed consent after being fully informed of and understanding the details of this clinical trial and the subject compliance requirements.\n\nExclusion Criteria:\n\n* Current or past history of clinically significant liver, kidney, neurological, psychiatric, respiratory, endocrine, hematologic, oncologic, genitourinary, cardiovascular, gastrointestinal, or musculoskeletal diseases.\n* History of gastrointestinal diseases (e.g., Crohn's disease, ulcers, acute or chronic pancreatitis) or gastrointestinal surgery (excluding simple appendectomy, hernia repair, or dental procedures) that may affect the absorption of the investigational product.\n* Pregnant (positive Urine-HCG test) or breastfeeding women.\n* History of clinically significant hypersensitivity (e.g., anaphylaxis or angioedema) to the investigational product ingredients, excipients, or other drugs (e.g., aspirin, penicillin-type antibiotics, macrolide antibiotics, etc.).\n* Clinically significant findings on 12-lead ECG at screening, including:\n\n  * QTc\\>450ms(males) or \\>470ms(females)\n  * PR intervals\\>200ms\n  * QRS duration\\>120ms\n* Clinically significant laboratory results at screening, including:\n\n  * Liver function (AST, ALT, ALP, γ-GT, and total bilirubin) exceeding 2 times the upper limit of normal (ULN).\n  * Serum creatinine outside the reference range, or eGFR calculated by the CKD-EPI formula \\\u003C 60 mL\u002Fmin\u002F1.73m2.\n* History of drug abuse or a positive response to drugs of abuse in the urine drug screen.\n* Vital signs measured in a sitting position after at least 3 minutes of rest at screening:\n\n  * Systolic Blood Pressure ≤ 90 mmHg or ≥ 150 mmHg\n  * Diastolic Blood Pressure ≤ 60 mmHg or ≥ 100 mmHg\n  * Pulse Rate ≤ 40 bpm or ≥ 100 bpm\n* Abnormal diet or consumption of food that may affect the absorption, distribution, metabolism, and excretion (ADME) of the investigational product.\n* Use of any prescription drugs or herbal medicines within 2 weeks, or any over-the-counter (OTC) drugs or health functional foods within 10 days before the first dose (unless deemed by the investigator not to affect the PK of the investigational product).\n* Use of drugs that induce or inhibit drug-metabolizing enzymes (e.g., barbiturates) within 1 month before the first dose.\n* Participation and dosing in another clinical trial within 6 months before the first dose.\n* Whole blood donation within 2 months, component donation within 1 month, or blood transfusion within 1 month before the first dose; or inability to refrain from donation during the study.\n* Consistent alcohol consumption exceeding 21 units\u002Fweek (1 unit = 10g of pure alcohol) within 6 months before the first dose, or inability to abstain from alcohol during the study.\n* Smokers who averaged \\> 10 cigarettes\u002Fday within 3 months before the first dose, or inability to quit smoking from 48 hours before the first dose until the last PK blood collection.\n* Consumption of food containing grapefruit within 72 hours before the first dose, or inability to abstain during the study.\n* Consumption of food containing caffeine (coffee, tea, soda, etc.) from 48 hours before each first dose until the last PK blood collection, or inability to abstain.\n* Strenuous exercise exceeding normal daily activities within 72 hours before the first dose, or inability to refrain from such exercise.\n* Subjects (or their partners) planning pregnancy, or those not using medically accepted methods of contraception (e.g., hormonal contraceptives, IUD, sterilization, barrier methods) from the time of consent until 2 weeks after the last dose.\n* Any other reason the investigator deems the subject unsuitable for participation in the clinical trial.",true,"ALL","19 Years",{"count":20,"type":21},60,"ESTIMATED","INTERVENTIONAL",[24],"PHASE1","A randomized, open-label, multiple-dose, crossover phase 1 clinical trial to compare and evaluate the safety, pharmacokinetics and pharmacodynamics characteristics after oral administration of UI059 and UIC202201 in healthy adult volunteers",[27],"Gastro Esophageal Reflux Disorder","NOT_YET_RECRUITING","2026-07-22",{"date":31,"type":32},"2026-07-27","ACTUAL",{"date":34,"type":21},"2026-07",{"date":36,"type":21},"2026-08",{"name":38,"class":39},"Korea United Pharm. Inc.","INDUSTRY",1,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":45,"acronym":4,"eligibilityCriteria":46,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":47,"enrollmentInfo":48,"targetDuration":4,"studyType":22,"phases":50,"briefSummary":45,"conditions":51,"keywords":4,"overallStatus":54,"whyStopped":4,"lastUpdateSubmitDate":55,"lastUpdatePostDateStruct":56,"startDateStruct":58,"completionDateStruct":60,"leadSponsor":62,"locationsCount":40},"100646839","phase-1-a-randomized-open-label-two-arm-two-period-multiple-dose-study-to-evaluate-pharmacokinetic-drug-drug-interaction-safety-and-tolerability-of-uic202601-and-uic202602-in-healthy-volunteers-100646839","NCT07682948","A Randomized, Open-label, Two-arm, Two-period, Multiple-dose, Study to Evaluate Pharmacokinetic Drug-drug Interaction, Safety and Tolerability of UIC202601 and UIC202602 in Healthy Volunteers","Inclusion Criteria:\n\n* Subjects aged 19 years or older and less than 55 years at the screening visit.\n* Subjects with a body weight of at least 50 kg (at least 45 kg for females) and a body mass index (BMI) of 18.0 kg\u002Fm² or higher and 30.0 kg\u002Fm² or lower at the screening visit.\n\nBMI (kg\u002Fm²) = Body weight (kg) \u002F Height (m)²\n\n* Subjects who have no clinically significant congenital or chronic diseases and no pathological symptoms or findings based on medical examination at the screening visit.\n* Subjects determined to be eligible for participation in the clinical trial by the Investigator (or delegated Sub-investigator) based on the evaluation results of hematology, blood chemistry, serology, urinalysis, other clinical laboratory tests, physical examination, and electrocardiogram (ECG), which are established and performed according to the characteristics of the investigational product.\n* Subjects who agree that they and\u002For their spouse or partner will use highly effective contraception (excluding hormonal contraceptives) from the first administration of the investigational product until 14 days after the last administration to prevent pregnancy and who agree not to donate sperm or ova.\n\n  * Highly effective methods of contraception: intrauterine device (IUD), bilateral tubal occlusion, vasectomized partner, sexual abstinence.\n* Subjects who have received and understood sufficient explanation regarding the purpose, procedures, characteristics of the investigational product, and anticipated adverse events of this clinical trial, and who have voluntarily signed the informed consent form.\n\nExclusion Criteria:\n\n* Subjects with current or past history of clinically significant diseases involving the renal system (e.g., severe renal impairment), nervous system (e.g., cerebrovascular disease), immune system, respiratory system (e.g., bronchial asthma), urinary system, gastrointestinal system, endocrine system (e.g., congenital lipid metabolism disorders, severe diabetes mellitus), hematologic\u002Foncologic system, cardiovascular system (e.g., severe hypertension, heart failure, coronary artery disease), reproductive system (e.g., endometrial hyperplasia, endometriosis), psychiatric disorders, or myopathy.\n* Subjects with a history of gastrointestinal surgery (except simple appendectomy or hernia repair) that may affect drug absorption, or with gastrointestinal disease.\n* Subjects with severe hepatic impairment, biliary obstruction, or cholestasis (this drug is excreted almost entirely via bile. Cholestasis, biliary obstructive disease, or hepatic impairment may be expected to reduce hepatic clearance.).\n* Subjects with active liver disease or persistent elevation of aminotransferase levels of unknown cause.\n* Subjects with hereditary angioedema or a history of angioedema during treatment with an ACE inhibitor or an angiotensin II receptor blocker.\n* Subjects who have taken enzyme-inducing or enzyme-inhibiting drugs such as barbiturates within 1 month before the first administration, or who have taken medications that may interfere with this clinical trial within 10 days before the first administration (however, participation may be allowed after considering pharmacokinetic and pharmacodynamic characteristics such as interactions with the investigational product and drug half-life).\n* Subjects who have consumed grapefruit-containing foods within 7 days before the first administration or who are unable to refrain from consuming such foods during the clinical trial.\n* Subjects who have participated in another clinical trial or bioequivalence study and received an investigational product within 6 months before the first administration.\n* Subjects who have donated whole blood within 8 weeks before the first administration, donated blood components within 2 weeks, or received a blood transfusion within 4 weeks.\n* Subjects considered unsuitable for participation based on screening assessments performed within 30 days before the first administration of the investigational product.\n\n  * AST or ALT \\> 1.5 × the upper limit of the normal range.\n  * Total bilirubin \\> 1.5 × the upper limit of the normal range.\n  * eGFR (estimated Glomerular Filtration Rate), calculated using the MDRD (Modification of Diet in Renal Disease) equation, \\\u003C 60 mL\u002Fmin\u002F1.73m².\n  * Positive results for serologic tests (hepatitis B, hepatitis C, human immunodeficiency virus \\[HIV\\], or syphilis).\n  * After at least 5 minutes of rest, seated vital signs showing systolic blood pressure \\> 139 mmHg or \\\u003C 100 mmHg, or diastolic blood pressure \\> 90 mmHg or \\\u003C 60 mmHg.\n* Subjects who meet any of the following conditions within 1 month before the first administration.\n\n  * Average alcohol consumption exceeding 21 drinks\u002Fweek for males.\n  * Average alcohol consumption exceeding 14 drinks\u002Fweek for females.\n\n    (1 drink = 50 mL of soju, 30 mL of spirits, or 250 mL of beer.)\n  * Smoking more than 10 cigarettes per day on average.\n* Subjects who meet any of the following conditions.\n\n  * Subjects with hypersensitivity to this drug or any of its components.\n  * Subjects with hereditary problems of fructose or galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption.\n* Subjects whom the Investigator (or delegated Sub-investigator) considers unsuitable for participation in this clinical trial for reasons other than the above inclusion\u002Fexclusion criteria (e.g., excessive tattoos).\n* Subjects with a history of drug abuse within 1 year before screening or those with a positive urine drug screening test.\n* Female subjects who are pregnant, suspected to be pregnant, or breastfeeding.","54 Years",{"count":49,"type":21},36,[24],[52,53],"Hypertension","Dyslipidemia","RECRUITING","2026-06-28",{"date":57,"type":32},"2026-07-06",{"date":59,"type":21},"2026-07-01",{"date":61,"type":21},"2026-09",{"name":38,"class":39},{"id":64,"slug":65,"hasResults":11,"nctId":66,"briefTitle":67,"officialTitle":68,"acronym":4,"eligibilityCriteria":69,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":70,"targetDuration":4,"studyType":22,"phases":72,"briefSummary":73,"conditions":74,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":40},"100635151","phase-1-a-study-to-evaluate-the-safety-and-pharmacokinetics-of-ui087-compared-to-coadministration-of-uic202506-uic202507-and-uic202508-in-healthy-adult-volunteers-under-fasting-conditions-100635151","NCT07548957","A Study to Evaluate the Safety and Pharmacokinetics of UI087 Compared to Coadministration of UIC202506, UIC202507 and UIC202508 in Healthy Adult Volunteers Under Fasting Conditions","An Open-label, Randomized, Single-dose, 2-sequence, 2-period, Crossover Study to Evaluate the Safety and Pharmacokinetics of UI087 Compared to Coadministration of UIC202506, UIC202507 and UIC202508 in Healthy Adult Volunteers Under Fasting Conditions","Inclusion Criteria:\n\n* Subjects aged 19 years or older at the screening visit\n* Subjects with a body weight ≥ 50 kg (≥ 45 kg for females) and a body mass index (BMI) between 18.0 and 30.0 kg\u002Fm² at the screening visit\n\n  * BMI (kg\u002Fm²) = body weight (kg) \u002F {height (m)}²\n* Subjects without clinically significant congenital or chronic diseases and without pathological symptoms or findings based on medical examination at the screening visit\n* Subjects deemed eligible for participation based on diagnostic tests (hematology, blood chemistry, serology, urinalysis, etc.) and ECG, as determined by the investigator (or delegated sub-investigator) according to the characteristics of the investigational product\n* Subjects who agree to use medically acceptable contraception\\* (excluding hormonal methods) from the first dose until 7 weeks after the last dose of the investigational product, to prevent pregnancy for themselves or their spouse\u002Fpartner, and who agree not to donate sperm or ova\n\n  * Medically acceptable contraception: Use of intrauterine devices, vasectomy, tubal ligation, and\u002For barrier methods (male condom, female condom, cervical cap, diaphragm, sponge, etc.), or the use of spermicide in combination with at least two barrier methods\n* Subjects who voluntarily sign the informed consent form after receiving and fully understanding sufficient explanation regarding the purpose, procedures, characteristics of the investigational product, and expected adverse events of the clinical trial\n\nExclusion Criteria:\n\n* Subjects with clinically significant diseases or a history of diseases involving the gastrointestinal, cardiovascular, endocrine, respiratory, hematologic\u002Foncologic, infectious, renal and genitourinary, psychiatric\u002Fneurological, musculoskeletal, immune, ENT, dermatologic, or ophthalmologic systems\n* Subjects with a history of gastrointestinal surgery (excluding simple appendectomy or hernia repair) that may affect drug absorption, or with gastrointestinal diseases\n* Subjects who have taken enzyme-inducing or inhibiting drugs (e.g., barbiturates) within 1 month prior to the first dose, or medications that may affect the clinical trial within 10 days prior to the first dose (Participation may be allowed depending on pharmacokinetic\u002Fpharmacodynamic properties such as interactions and half- life)\n* Subjects who have participated in another clinical trial or bioequivalence study and received an investigational product within 6 months prior to the first dose\n* Subjects who have donated whole blood within 8 weeks, donated blood components within 2 weeks, or received a transfusion within 4 weeks prior to the first dose\n* Subjects meeting the following conditions within 1 month prior to the first dose:\n\n  * Alcohol consumption exceeding an average of 21 drinks\u002Fweek for males\n  * Alcohol consumption exceeding an average of 14 drinks\u002Fweek for females\n\n    (1 drink = 50 mL of soju, 30 mL of spirits, or 250 mL of beer)\n  * Smoking more than an average of 20 cigarettes per day\n* Subjects who meet the following:\n\n  * Hypersensitivity to the active ingredient, excipients of the investigational product, or a drug in the same class as the investigational product\n  * Genetic disorders such as galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption\n* Subjects with the following conditions:\n\n  * Type 1 diabetes mellitus, lactic acidosis, or acute\u002Fchronic metabolic acidosis including diabetic ketoacidosis (with or without coma), or a history of ketoacidosis\n  * Moderate (stage 3b) or severe renal impairment (GFR \\\u003C 45 mL\u002Fmin\u002F1.73 m²), or acute conditions that may affect renal function such as dehydration, severe infection, cardiovascular collapse (shock), acute myocardial infarction, or sepsis\n  * Acute or unstable heart failure\n  * Patients undergoing intravascular iodinated contrast imaging (e.g., intravenous urography, cholangiography, angiography, contrast-enhanced CT, etc.)\n  * Diabetic pre-coma\n  * Severe infections or severe traumatic systemic disorders\n  * Patients scheduled for surgery\n  * Patients with malnutrition, starvation, debility, hypopituitarism, or adrenal insufficiency\n  * Patients with acute or chronic conditions that may cause tissue hypoxia (e.g., hepatic impairment, respiratory failure, acute myocardial infarction, shock)\n  * Patients with excessive alcohol intake or gastrointestinal disorders such as dehydration, diarrhea, or vomiting\n* Subjects deemed unsuitable for participation by the investigator (or delegated sub-investigator) for any other reason not specified above\n* Female subjects who are pregnant, suspected to be pregnant, or breastfeeding",{"count":71,"type":21},44,[24],"This study was an open-label, randomized, single-dose, 2-sequence, 2-period, crossover study to evaluate the safety and pharmacokinetics of UI087 compared to coadministration of UIC202506, UIC202507 and UIC202508 in healthy adult volunteers under fasting conditions",[75],"Diabetes Mellitus (Type 2)","2026-04-21",{"date":78,"type":32},"2026-04-23",{"date":80,"type":21},"2026-04",{"date":82,"type":21},"2026-10",{"name":38,"class":39},{"id":85,"slug":86,"hasResults":11,"nctId":87,"briefTitle":88,"officialTitle":88,"acronym":4,"eligibilityCriteria":89,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":90,"targetDuration":4,"studyType":22,"phases":92,"briefSummary":93,"conditions":94,"keywords":4,"overallStatus":54,"whyStopped":4,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":40},"100605432","phase-1-a-two-arm-open-label-single-sequence-multiple-dose-cross-over-study-to-evaluate-the-pharmacokinetic-interaction-and-the-safety-of-uic202502-and-uic202505-in-healthy-adult-volunteers-100605432","NCT07162441","A Two-arm, Open-label, Single-sequence, Multiple-dose, Cross-over Study to Evaluate the Pharmacokinetic Interaction and the Safety of UIC202502 and UIC202505 in Healthy Adult Volunteers","Inclusion Criteria:\n\n* Subjects aged 19 years or older at the time of screening.\n* Subjects with a body weight greater than 50 kg (≥45 kg for females) and a body mass index (BMI) between 18.0 and 30.0 kg\u002Fm² at screening.\n\n(BMI (kg\u002Fm²) = weight (kg) \u002F height (m)²)\n\n* Subjects with no clinically significant congenital or chronic diseases, pathological symptoms or findings at screening.\n* Subjects determined by the principal investigator to be suitable for diagnostic procedures and electrocardiogram assessments\n* Subjects who agree to use an effective method of contraception (excluding hormonal agents) recognized as appropriate in clinical trials from the first administration of the investigational drug until 14 days after the last administration, together with their spouse or partner.\n* Subjects who have provided written informed consent after receiving a full explanation and demonstrating an understanding of the purpose, procedures, and characteristics of this clinical trial and the investigational drug.\n\nExclusion Criteria:\n\n* Subjects with clinically significant diseases or a history of conditions involving the digestive, cardiovascular, endocrine, respiratory, hematologic\u002Foncologic infectious, renal\u002Fgenitourinary, psychiatric\u002Fneurologic, musculoskeletal, immune, otorhinolaryngologic, dermatologic, or ophthalmologic systems.\n* Subjects with a history of gastrointestinal surgery (excluding simple appendectomy or hernia repair) or gastrointestinal disease that may affect drug absorption.\n* Subjects who have taken drugs that induce or inhibit drug-metabolizing enzymes (e.g., barbiturates) within 1 month before the first dose, or drugs that may interfere with this clinical trial within 10 days before the first dose\n* Subjects who have participated in another clinical trial or bioequivalence study and received an investigational drug within 6 months before the first administration.\n* Subjects who have donated whole blood or blood components within 2 weeks, or received a blood transfusion within 4 weeks before the first administration.\n* Subjects who meet any of the following criteria within 1 month before the first dose:\n\n  * Average alcohol consumption exceeding 21 drinks\u002Fweek for men\n  * Average alcohol consumption exceeding 14 drinks\u002Fweek for women\n\n    (1 drink = 50 mL soju, 30 mL liquor, or 250 mL beer)\n  * Smoking more than 20 cigarettes\u002Fday on average\n* Subjects judged by the principal investigator to be unsuitable for participation in this clinical trial for any reason other than the above selection or exclusion criteria.\n* Female subjects who are pregnant, suspected of being pregnant, or lactating",{"count":91,"type":21},50,[24],"This study is open-label, multiple-dose, two-intervention group, single-sequence, crossover design to compare the safety and pharmacokinetics of UIC202502 and UIC202505 when administered alone or in combination.",[53],"2025-08-31",{"date":97,"type":32},"2025-09-09",{"date":99,"type":32},"2025-08-12",{"date":101,"type":21},"2026-03-01",{"name":38,"class":39},""]